Galena Biopharma, Inc’s (GALE - Free Report) shares plunged 82.8% after the company announced that it has discontinued the phase III PRESENT study on its lead candidate, NeuVax (nelipepimut-S). The decision followed the …
ZACKS11mon
NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds …
GALE-301 is a cancer immunotherapy consisting of a peptide derived ... Closed a Public Offering of Common Stock and Warrants On February 12, 2017, the Company closed the previously announced underwritten public offering of common …
Galena Biopharma
Maxim Group have a $4.00 target on the stock. The target would suggest a potential upside of 150.00 % from Galena Biopharma (NASDAQ:GALE)’s previous stock close. This rating was disclosed to clients in analysts note on Tuesday …
The drama unfolded under picture-book skies on Bermuda’s Great Sound, where …
Team USA
Shares of Galena Biopharma Inc. (GALE), a developer ... (See also: What Are Reverse Stock Splits?) Galena’s board approved the reverse 1-for-20 stock split on October 26. (See also: Xoma Declares 1-for-20 Reverse Stock Split.)
Split
Galena Biopharma Inc (NASDAQ:GALE)'s stock had its "outperform" rating reaffirmed by analysts at FBR & Co. in a note issued to investors on Saturday, AnalystRatings.NET reports. They presently have a $1.50 price target on the …
We'll see. I'm working on a couple of different things to maybe be able to come back." In the tenuous world of stock-car financing, Gale can't say yet what next season holds for him, although NASCAR is entering its "silly season," when …
This rating was issued on 2/06/17. The stock's market capitalization is 5.96M, it has a 52-week low of 0.53 and a 52-week high of 49.80. Sell-side analyst recommendations point to a short term price target of $14.84 on the company shares. …
NASDAQ